drugset / Trial / NCT03456713

A Study of LY3074828 in Healthy Participants

NCT03456713

Phase 1 Completed 72 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828, when given as a solution formulation in different devices. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening.

Timeline

Start
2018-03-06
Primary completion
2018-08-13
Completion
2018-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirikizumab Monoclonal antibody 125 mg Subcutaneous
Subject Mirikizumab Monoclonal antibody 250 mg Subcutaneous

Indications

No indication recorded.